TOKYO -- The success of Daiichi Sankyo's blockbuster cancer drug Enhertu has helped propel it into the ranks of Japan's most valuable companies, lifting its market capitalization above 10 trillion yen ($64 billion) on rising growth expectations.
Speaking Tuesday at the American Society of Clinical Oncology's annual meeting in Chicago, executives from the drugmaker indicated that they look to expand the use of Enhertu in the U.S.
